Clinical Trials Logo

Mucopolysaccharidosis II clinical trials

View clinical trials related to Mucopolysaccharidosis II.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03041324 Terminated - Clinical trials for Mucopolysaccharidosis II

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Start date: May 11, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. SB-913 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts a correct copy of the IDS gene into the Albumin locus in hepatocytes with the goal of lifelong therapeutic production of the IDS enzyme.

NCT ID: NCT01675674 Terminated - Clinical trials for Mucopolysaccharidosis II

Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics

Start date: September 2011
Phase: N/A
Study type: Observational

This study is being done to learn how many children and young adults who come to pediatric rheumatology clinics may have mucopolysaccharidosis (MPS). The study tests for 4 of the types of MPS: I, II, IVA, and VI. This can help researchers decide whether to create a screening program for MPS at pediatric rheumatology clinics. This study is being done in rheumatology clinics because the first symptoms of MPS are often joint problems such as stiff joints, and rheumatologists may be the first doctors that a patient with MPS visits. The study will also evaluate the utility of dried blood spot testing for MPS.

NCT ID: NCT01372228 Terminated - Sandhoff Disease Clinical Trials

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Start date: April 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this research study is to establish chimerism and avoid graft-versus-host-disease (GVHD) in patients with inherited metabolic disorders.

NCT ID: NCT01330277 Terminated - Clinical trials for Mucopolysaccharidosis II

Biomarkers for Hunter Syndrome

BioHunter
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to establish Hunter Syndrom biomarker/s and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

NCT ID: NCT00748969 Terminated - Clinical trials for Mucopolysaccharidosis II

Clinical Trial of Growth Hormone in MPS I, II, and VI

Start date: November 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.